BioMerieux (XPAR:BIM) FCF Margin % : 5.75% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is BioMerieux FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioMerieux's Free Cash Flow for the six months ended in Dec. 2023 was €110 Mil. BioMerieux's Revenue for the six months ended in Dec. 2023 was €1,905 Mil. Therefore, BioMerieux's FCF Margin % for the quarter that ended in Dec. 2023 was 5.75%.

As of today, BioMerieux's current FCF Yield % is 0.89%.

The historical rank and industry rank for BioMerieux's FCF Margin % or its related term are showing as below:

XPAR:BIM' s FCF Margin % Range Over the Past 10 Years
Min: 2.91 Med: 6.08 Max: 15.83
Current: 2.91

During the past 13 years, the highest FCF Margin % of BioMerieux was 15.83%. The lowest was 2.91%. And the median was 6.08%.

XPAR:BIM's FCF Margin % is ranked better than
66.52% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.51 vs XPAR:BIM: 2.91

BioMerieux FCF Margin % Historical Data

The historical data trend for BioMerieux's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux FCF Margin % Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

5.06

9.79

15.83

5.25

2.91

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															21.77	0.83	9.04	-0.14	5.75

Competitive Comparison of BioMerieux's FCF Margin %

For the Diagnostics & Research subindustry, BioMerieux's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMerieux's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioMerieux's FCF Margin % falls into.

BioMerieux FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioMerieux's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	107.1	/	3674.6
	=	2.91 %

BioMerieux's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	109.5	/	1904.5
	=	5.75 %

BioMerieux FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioMerieux's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux (XPAR:BIM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines